IceCure Medical Ltd
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ICCM research report →
Range $1 – $1
Price Chart
About the company
Headquartered in Caesarea, Israel, and founded in 2006, IceCure Medical Ltd is a medical device enterprise dedicated to inventing, refining, and marketing innovative solutions for treating human tumors through cryoablation, a freezing process. Their primary offering, the ProSense system, provides a specialized cryoablation therapy specifically for breast tumors.
- CEO
- Eyal Shamir
- IPO
- 2021
- Employees
- 68
- HQ
- Caesarea, HA, IL
Get TickerSpark's AI analysis on ICCM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.80M
- P/E
- -0.14
- Fwd P/E
- 2.67
- PEG
- -0.00
- P/S
- 0.46
- P/B
- 0.49
- EV/EBITDA
- 0.34
- Div Yield
- 0.00%
- Gross Margin
- 34.74%
- Op Margin
- -213.19%
- Net Margin
- -439.71%
- ROE
- -180.46%
- ROIC
- -88.17%
Latest fiscal year · YoY change
- Revenue
- $3.38M+2.7%
- Gross Profit
- $1.23M-15.5%
- Op Income
- $-15,094,000
- Net Income
- $-15,057,000+1.7%
- EPS
- $-7.10+21.1%
- OCF Growth
- -16.0%
- FCF Growth
- -15.6%
- 52W High
- $22.20
- 52W Low
- $0.65
- 50D MA
- $1.22
- 200D MA
- $6.57
- Beta
- 0.43
- RSI (14)
- 41
- Avg Volume
- 186.02K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
IceCure said third-quarter and nine-month 2026 results showed continued ProSense momentum, led by 26% revenue growth and 83% U.S. sales growth, while management kept emphasizing commercial expansion and the ChoICE study.· November 18, 2026
- Total revenue for the first nine months of 2026 rose 26% year over year to $2.6 million.
- U.S. sales increased 83% year over year as the company expanded its commercial footprint from 11 states to 21 states.
- Gross profit increased to $762,000 from $626,000, while operating loss widened to $12.9 million.
- Management said ChoICE is now at four sites, with more sites expected to come online over the next couple of months.
- Guidance was limited, but management said next year revenue should see healthy double-digit growth and Q4 should be better than Q3.
For the first nine months of 2026, total revenue increased approximately 26% to $2.6 million from $2.1 million in the prior-year period. Gross profit rose approximately 22% to $762,000 from $626,000. U.S. sales increased 83% year over year, while R&D expense was approximately $6.5 million versus $5.1 million, sales and marketing expense was $3.6 million versus $3.0 million, and G&A was $3.5 million versus $3.3 million. Operating loss and net loss were both approximately $12.9 million, compared with $10.8 million a year earlier. Cash and cash equivalents were approximately $8.2 million as of September 30, 2026, versus $8.9 million at year-end 2025. On outlook, management said Q4 is normally the best quarter and should be better than Q3, and they projected next year revenue growth would be healthy double digits.
Eyal Shamir framed the quarter as evidence that IceCure is translating its clinical and regulatory base into commercial growth, especially in the U.S. He highlighted the nearly doubled U.S. footprint, added sales and clinical support, continued patient enrollment in ChoICE, and international progress including China approval and a Netherlands distribution agreement. His tone was constructive but still cautious, repeatedly noting the company is still early in realizing the full commercial opportunity for ProSense.
Meir Peleg focused on the nine-month financials and the company’s capital discipline. He cited $2.6 million in revenue, $762,000 in gross profit, and a $12.9 million operating loss, and said R&D rose because of ChoICE and other clinical work while sales and marketing increased with the U.S. expansion. He also noted cash and cash equivalents of $8.2 million and said the company is carefully managing resources while investing in commercial, clinical, and organizational capabilities.
Analysts focused on whether Q4 would repeat last year’s sequential revenue jump, and management said U.S. sales should continue to rise quarter over quarter while Q4 is normally the strongest quarter, though they would not say it will match last year. Questions also centered on ChoICE timing and enrollment targets; management said the study is currently at four sites, expects a steadier cadence of new sites, and acknowledged it may be difficult to hit 400 patients exactly within three years, though they are in ongoing dialogue with the FDA. Internationally, management said China go-to-market efforts are in partner discussions, Health Canada approval could come in the next few months, and Japan filing by Terumo is expected in the first half of 2027.
The bull case is that U.S. commercial traction appears to be building, with sales up 83% and the footprint expanding to 21 states. Management also pointed to improving physician adoption, early positive feedback from experienced and new users in ChoICE, and additional international opportunities from China, the Netherlands, Canada, and Japan.
The company is still small in absolute revenue, with $2.6 million in nine-month sales against $12.9 million in operating loss. ChoICE enrollment appears slower than earlier expectations, management said 400 patients in three years may be difficult, and the cash balance of $8.2 million suggests continued reliance on execution and discipline to fund growth.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 77.0%
- Shares Outstanding
- 2.25M
- Float Shares
- 1.74M
of shares held by institutions
19 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 2, 26 | Shamir Eyal | other | 404,901 |
| Nov 2, 26 | Mayron Ron | other | 166,577 |
| Aug 14, 26 | Good Shad | other | 131,483 |
| Aug 12, 26 | Salton David | other | 0 |
| Aug 14, 26 | Tel-Tzure Tlalit Bussi | other | 101,483 |
| Aug 14, 26 | Levav Shay | other | 141,483 |
| Aug 14, 26 | Dotan Merav Nir | other | 73,890 |
| Aug 14, 26 | Peleg Meir | other | 181,483 |
| Aug 12, 26 | Chan Vincent Chun Hung | other | 0 |
| Apr 12, 26 | Muchnik Naum | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ICCM coverage
Recent articles, reports, and earnings notes.
No research on ICCM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ICCM report →IceCure: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 18
IceCure Medical Ltd (ICCM) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 18
IceCure Medical Ltd. (ICCM) Reports Q3 Loss, Misses Revenue Estimates
zacks.com · Nov 18
IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2026: 83% Year-Over-Year Growth in U.S. Sales and Major Growth in U.S. Commercial Reach to 21 States
prnewswire.com · Nov 18
IceCure Medical to Report Third Quarter 2026 Financial and Operating Results on November 18, 2026
prnewswire.com · Nov 11
IceCure Granted New Patent in China for Its Cryogenic System Connector, Expanding Its Global IP Portfolio
prnewswire.com · Nov 9
IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation
prnewswire.com · Oct 27
IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites
prnewswire.com · Oct 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.